Home > Offer to Sell > Pharmaceuticals and Biochemicals > Antineoplastics agents > Bortezomib 179324-69-7

Bortezomib 179324-69-7

  Post Date: May 07,2019
  Expiry Date: Nov 03,2019
  Detailed Description: Cas No. :179324-69-7 Bortezomib is the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells. Targets the ubiquitin-proteasome pathway.

  CAS Registry Number:


  Synonyms: ;VELCADE;dpba;[(1r)-3-methyl-1-[[(2s)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-boronic acid;VELCADE(BORTEZOMIB);Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-;Bortezomib for research;N-[(1S)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-D-phenylalaninamide;N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide;Bortizomib;
  Molecular Formula: C19H25BN4O4
  Molecular Weight: 384.2372
  Molecular Structure: 179324-69-7 Bortezomib

  Company: Shanghai Neopharm Co., Ltd.     [ China ]          
  Contact: Carol Zhu
  Tel: 021-58826758
  Fax: 021-58827258
  Email: sales@neopharm.com.cn
Disclaimer statement:The information and data included above have been realized by the enterprises and compiled by the staff, and are subject to change without notice to you. The Chemnet makes no warranties or representations whatsoever regarding the facticity, accuracy and validity of such information and data. In order to ensure your interest, we suggest you chose the products posted by our gold suppliers or VIP members.